100
Participants
Start Date
June 20, 2016
Primary Completion Date
December 16, 2019
Study Completion Date
December 16, 2019
INCAGN01876
Initial cohort dose of INCAGN01876 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
Memorial Sloan Kettering Cancer Center, New York
MSK Westchester, Harrison
Vanderbilt University Medical Center, Nashville
The Angeles Clinic and Research Institute, Los Angeles
Yale University, New Haven
Beth Israel Deaconess Medical Center, Boston
Dana Farber Cancer Institute, Boston
Memorial Sloan Kettering at Monmouth, Middletown
Lead Sponsor
Incyte Biosciences International Sàrl
INDUSTRY